<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Transl Allergy</journal-id><journal-id journal-id-type="iso-abbrev">Clin Transl Allergy</journal-id><journal-title-group><journal-title>Clinical and Translational Allergy</journal-title></journal-title-group><issn pub-type="epub">2045-7022</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3354095</article-id><article-id pub-id-type="publisher-id">2045-7022-1-S1-O37</article-id><article-id pub-id-type="doi">10.1186/2045-7022-1-S1-O37</article-id><article-categories><subj-group subj-group-type="heading"><subject>Oral Presentation</subject></subj-group></article-categories><title-group><article-title>The level of specific IgE is a moderate predictor for the outcome of a double-blind placebo-controlled food challenge for hazelnut in children</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Masthoff</surname><given-names>Laury</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Pasmans</surname><given-names>Suzanne</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Knol</surname><given-names>Mirjam</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>van Hoffen</surname><given-names>Els</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Flinterman</surname><given-names>Annebeth</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Kentie</surname><given-names>Petra</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Knulst</surname><given-names>Andr&#x000e9;</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Meijer</surname><given-names>Yolanda</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib></contrib-group><aff id="I1"><label>1</label>University Medical Center Utrecht, (Pediatric) Dermatology/Allergology, Utrecht, Netherlands</aff><aff id="I2"><label>2</label>University Medical Center Utrecht, (Pediatric) Dermatology/Allergology, Center of Pediatric Allergology, Wilhelmina Children's Hospital, Pediatric Pulmonology, Utrecht, Netherlands</aff><aff id="I3"><label>3</label>University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, Utrecht, Netherlands</aff><aff id="I4"><label>4</label>University Medical Center Utrecht, Center of Pediatric Allergology, Wilhelmina Children's Hospital, Pediatric Pulmonology, Utrecht, Netherlands</aff><pub-date pub-type="collection"><year>2011</year></pub-date><pub-date pub-type="epub"><day>12</day><month>8</month><year>2011</year></pub-date><volume>1</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Food Allergy and Anaphylaxis Meeting 2011</named-content><named-content content-type="supplement-editor">Antonella Muraro. Co-Editors Ren&#x000e9; Crevel, Stefan Vieths, Susanne Halken, Andrew Clark, Graham Roberts, Anthony Dubois, Thomas Werfel, Karin Hoffman-Sommergruber, Philippe Eigenmann and Clare Mills</named-content></supplement><fpage>O37</fpage><lpage>O37</lpage><permissions><copyright-statement>Copyright &#x000a9;2011 Masthoff et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>Masthoff et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.ctajournal.com/content/1/S1/O37"/><conference><conf-date>17-19 February 2011</conf-date><conf-name>Food Allergy and Anaphylaxis Meeting 2011</conf-name><conf-loc>Venice, Italy</conf-loc></conference></article-meta></front><body><sec><title/><p>Literature about the value of diagnostic tests for hazelnut allergy in children is scarce. For peanut allergy cutoff levels of specific IgE with a 95% positive predictive value (PPV) were published. To evaluate current diagnostics for hazelnut allergy in children, data of 151 children, who underwent a double-blind placebo-controlled food challenge (DBPCFC) for hazelnut were analyzed. The PPV or negative predictive value (NPV) of the level of specific IgE (CAP) for hazelnut and the size of the skin prick test (SPT) for hazelnut was determined. The influence of spiking of the CAP for hazelnut with rCor a 1 was analyzed. The level of specific IgE for hazelnut was a moderate predictor for a positive DBPCFC for hazelnut. No cutoff levels of specific IgE for hazelnut with a 95% PPV could be determined. Before Cor a 1 spiking the maximum reached PPV was 73% for a cutoff level of 26 kUA/L, after spiking the maximum reached PPV was 64% for a cutoff level of 31 kUA/L. The spiking increased the NPV from 91% to 100% for a cutoff level of 0.35 kUA/L. SPT was a better predictor for a positive DBPCFC compared to the level of specific IgE. When the SPT &#x0003e;16 mm, the PPV was 100%. By combining both tests, the PPV reached 100% when the level of specific IgE for hazelnut was &#x0003e;5 kUA/L and the level of SPT was &#x0003e;12mm. However, the PPV of 100% for SPT alone and the combination of CAP and SPT accounted for only 11% respectively 13% of the children undergoing a DBPCFC for hazelnut. So, the level of specific IgE and reactivity of SPT are moderate predictors for the outcome of a DBPCFC for hazelnut in children. New diagnostic tools are needed to replace the DBPCFC which is burdensome, expensive and limited available.</p></sec></body></article>